Reports
Sale
Global Rituximab Biosimilars Market Share, Size, Trends, Growth, Analysis: By Product Type: Blitzima, Rixathon, Others; By Indication Type: Non-Hodgkin’s Lymphoma, Chronic Lymphocytic Leukemia, Rheumatoid Arthritis, Others; By Distribution Channels: Hospital Based Pharmacies, Others; Regional Analysis; Supplier Landscape; 2024-2032
Global Rituximab Biosimilars Market Outlook
The global rituximab biosimilars market size was valued at USD 2.37 billion in 2023 and is projected to grow at a CAGR of 15.7% during the forecast period of 2024-2032 to reach a value of USD 8.81 billion by 2032. The market growth can be attributed to the increasing prevalence of autoimmune diseases, cancer, and the rising demand for cost-effective alternatives to branded biologics.
Rituximab Biosimilars Market Report Snapshots
Rituximab Biosimilars Market Size
Rituximab Biosimilars Market Trends
Rituximab Biosimilars Market Companies
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
2 Research Methodology
3 Executive Summary
4 Rituximab Biosimilars Overview
4.1 Drug Overview
4.1.1 Pharmacodynamics
4.1.2 Pharmacokinetics
4.1.3 Adverse Events
5 Patient Profile
5.1 Patient Profile Overview
5.2 Patient Psychology and Emotional Impact Factors
5.3 Risk Assessment and Treatment Success Rate
6 Global Rituximab Biosimilars Market
6.1 Global Rituximab Biosimilars Market Overview
6.2 Global Rituximab Biosimilars Market Analysis
6.2.1 Market Overview
6.2.1.1 Global Rituximab Biosimilars Market Historical Value (2017-2023)
6.2.1.2 Global Rituximab Biosimilars Market Forecast Value (2024-2032)
6.3 Global Rituximab Biosimilars Market by Product Type
6.3.1 Market Overview
6.3.1.1 Blitzima
6.3.1.2 Rixathon
6.3.1.3 Others
6.4 Global Rituximab Biosimilars Market by Indication Type
6.4.1 Market Overview
6.4.1.1 Non-Hodgkin’s Lymphoma
6.4.1.2 Chronic Lymphocytic Leukemia
6.4.1.3 Rheumatoid Arthritis
6.4.1.4 Others
6.5 Global Rituximab Biosimilars Market by Distribution Channels
6.5.1 Market Overview
6.5.1.1 Hospital-Based Pharmacies
6.5.1.2 Online Pharmacies
6.5.1.3 Retail Pharmacies
6.6 Global Rituximab Biosimilars Market by Region
6.6.1 Market Overview
6.6.1.1 North America
6.6.1.2 Europe
6.6.1.3 Asia Pacific
6.6.1.4 Latin America
6.6.1.5 Middle East and Africa
7 North America Rituximab Biosimilars Market
7.1 Market Share by Country
7.2 United States of America
7.2.1 Historical Trend (2017-2023)
7.2.2 Forecast Trend (2024-2032)
7.3 Canada
7.3.1 Historical Trend (2017-2023)
7.3.2 Forecast Trend (2024-2032)
8 Europe Rituximab Biosimilars Market
8.1 Market Share by Country
8.2 United Kingdom
8.2.1 Historical Trend (2017-2023)
8.2.2 Forecast Trend (2024-2032)
8.3 Germany
8.3.1 Historical Trend (2017-2023)
8.3.2 Forecast Trend (2024-2032)
8.4 France
8.4.1 Historical Trend (2017-2023)
8.4.2 Forecast Trend (2024-2032)
8.5 Italy
8.5.1 Historical Trend (2017-2023)
8.5.2 Forecast Trend (2024-2032)
8.6 Others
9 Asia Pacific Rituximab Biosimilars Market
9.1 Market Share by Country
9.2 China
9.2.1 Historical Trend (2017-2023)
9.2.2 Forecast Trend (2024-2032)
9.3 Japan
9.3.1 Historical Trend (2017-2023)
9.3.2 Forecast Trend (2024-2032)
9.4 India
9.4.1 Historical Trend (2017-2023)
9.4.2 Forecast Trend (2024-2032)
9.5 ASEAN
9.5.1 Historical Trend (2017-2023)
9.5.2 Forecast Trend (2024-2032)
9.6 Australia
9.6.1 Historical Trend (2017-2023)
9.6.2 Forecast Trend (2024-2032)
9.7 Others
10 Latin America Rituximab Biosimilars Market
10.1 Market Share by Country
10.2 Brazil
10.2.1 Historical Trend (2017-2023)
10.2.2 Forecast Trend (2024-2032)
10.3 Argentina
10.3.1 Historical Trend (2017-2023)
10.3.2 Forecast Trend (2024-2032)
10.4 Mexico
10.4.1 Historical Trend (2017-2023)
10.4.2 Forecast Trend (2024-2032)
10.5 Others
11 Middle East and Africa Rituximab Biosimilars Market
11.1 Market Share by Country
11.2 Saudi Arabia
11.2.1 Historical Trend (2017-2023)
11.2.2 Forecast Trend (2024-2032)
11.3 United Arab Emirates
11.3.1 Historical Trend (2017-2023)
11.3.2 Forecast Trend (2024-2032)
11.4 Nigeria
11.4.1 Historical Trend (2017-2023)
11.4.2 Forecast Trend (2024-2032)
11.5 South Africa
11.5.1 Historical Trend (2017-2023)
11.5.2 Forecast Trend (2024-2032)
11.6 Others
12 Global Rituximab Biosimilars Market Dynamics
12.1 Market Drivers and Constraints
12.2 Drug Adoption Parameters
12.3 SWOT Analysis
12.4 Porter Five Forces Model
12.5 Key Demand Indicators
12.6 Key Price Indicators
12.7 Industry Events, Initiatives, and Trends
12.8 Value Chain Analysis
13 Supplier Landscape
13.1 Innovent Biologics Inc
13.1.1 Company Overview
13.1.2 Product Portfolio
13.1.3 Demographic Reach and Achievements
13.1.4 Mergers and Acquisitions
13.1.5 Certifications
13.2 Gedeon Richter Plc.
13.2.1 Company Overview
13.2.2 Product Portfolio
13.2.3 Demographic Reach and Achievements
13.2.4 Mergers and Acquisitions
13.2.5 Certifications
13.3 BioXpress Therapeutics SA
13.3.1 Company Overview
13.3.2 Product Portfolio
13.3.3 Demographic Reach and Achievements
13.3.4 Mergers and Acquisitions
13.3.5 Certifications
13.4 Teva Pharmaceutical Industries Ltd.
13.4.1 Company Overview
13.4.2 Product Portfolio
13.4.3 Demographic Reach and Achievements
13.4.4 Mergers and Acquisitions
13.4.5 Certifications
13.5 Takeda Pharmaceutical Company Limited
13.5.1 Company Overview
13.5.2 Product Portfolio
13.5.3 Demographic Reach and Achievements
13.5.4 Mergers and Acquisitions
13.5.5 Certifications
13.6 Sandoz International GmbH (Novartis)
13.6.1 Company Overview
13.6.2 Product Portfolio
13.6.3 Demographic Reach and Achievements
13.6.4 Mergers and Acquisitions
13.6.5 Certifications
13.7 Zydus Lifesciences Ltd.
13.7.1 Company Overview
13.7.2 Product Portfolio
13.7.3 Demographic Reach and Achievements
13.7.4 Mergers and Acquisitions
13.7.5 Certifications
13.8 Hetero Drugs Limited
13.8.1 Company Overview
13.8.2 Product Portfolio
13.8.3 Demographic Reach and Achievements
13.8.4 Mergers and Acquisitions
13.8.5 Certifications
13.9 Dr Reddy's Laboratories Ltd
13.9.1 Company Overview
13.9.2 Product Portfolio
13.9.3 Demographic Reach and Achievements
13.9.4 Mergers and Acquisitions
13.9.5 Certifications
13.10 Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
13.10.1 Company Overview
13.10.2 Product Portfolio
13.10.3 Demographic Reach and Achievements
13.10.4 Mergers and Acquisitions
13.10.5 Certifications
13.11 Zenotech Laboratories
13.11.1 Company Overview
13.11.2 Product Portfolio
13.11.3 Demographic Reach and Achievements
13.11.4 Mergers and Acquisitions
13.11.5 Certifications
13.12 Napp Pharmaceuticals Limited
13.12.1 Company Overview
13.12.2 Product Portfolio
13.12.3 Demographic Reach and Achievements
13.12.4 Mergers and Acquisitions
13.12.5 Certifications
13.13 Mundipharma International Limited
13.13.1 Company Overview
13.13.2 Product Portfolio
13.13.3 Demographic Reach and Achievements
13.13.4 Mergers and Acquisitions
13.13.5 Certifications
14 Pricing Models and Strategies (Additional Insight)
14.1 Cost Model
14.1.1 Manufacturing Cost Analysis
14.1.2 Procurement Cost Analysis
14.2 Pricing Strategies
14.2.1 Competitor Pricing Analysis
14.2.2 Key Assessment of Product Attributes
14.2.3 Pricing Benchmark
15 Global Rituximab Biosimilars Market- Distribution Model (Additional Insight)
15.1 Overview
15.2 Potential Distributors
15.3 Key Parameters for Distribution Partner Assessment
*Additional insights provided are customisable as per client requirements.
Key Questions Answered in the Report
The factors stimulating the development of the market are increased government initiatives, optimal biosimilars costs, and a rise in R&D expenditure in biopharmaceutical companies.
Fewer drug approvals, stringent government regulations, and lack of awareness are the suspected reasons for hindering the growth of this market.
Based on the product type, the market is categorised into blitzima and rixathon, among others.
Based on the indication, the market is divided into non-Hodgkin’s Lymphoma, chronic lymphocytic leukaemia, and rheumatoid arthritis, among others.
The distribution channels are hospital-based pharmacies, retail pharmacies, and online pharmacies.
Based on the region, the market is segmented into North America, Europe, Asia Pacific, Latin America, the Middle East and Africa.
The trade name for rituximab is Rituxan.
Truxima is the biosimilar of the rituximab reference drug.
A biosimilar is a copy of a biologic medicine that is similar, but not identical, to the original drug.
Biosimilars are available at low costs and thus, have the potential to enhance treatment accessibility.
Rituximab and its biosimilars are primarily used to treat rheumatoid arthritis, lymphoma, and leukaemia.
The major companies involved are Innovent Biologics Inc, Gedeon Richter Plc., BioXpress Therapeutics SA, Teva Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Sandoz International GmbH (Novartis), Zydus Lifesciences Ltd., Hetero Drugs Limited, Dr Reddy's Laboratories Ltd, Shanghai Fosun Pharmaceutical (Group) Co., Ltd., Zenotech Laboratories, Napp Pharmaceuticals Limited, and Mundipharma International Limited, among others.
Purchase Options 10% off
Call us
Purchase Full Report
Datasheet
$ 2969
$2699
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 5499
$4999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 6599
$5999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 7699
$6999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER